|Work hours||Add information|
|About||Pertinax Pharma Ltd is developing dental, medical and veterinary applications of a new long acting formulation of chlorhexidine, also called Pertinax™|
Dr Michele Barbour and her research group at the University of Bristol (UoB) have been developing and characterising sustained efficacy antimicrobial materials for over 10 years. The group has developed a novel material which acts as a slow release technology for chlorhexidine (CHX). CHX is a common, safe and cheap biocide which is in widespread use, but is limited in its current applications owing to its short retention times. This novel formulation of CHX can be applied as a coating or filler for a variety of materials and devices, to confer a lasting antibacterial and antifungal protection. In April 2015, Pertinax Pharma Ltd was established to exploit the numerous commercial applications of the controlled release CHX technology, also called Pertinax™.
There are many applications of Pertinax, including in the field of medical devices, wound care and human and veterinary consumer healthcare. Pertinax can be used to provide augmented function to existing devices and materials, such as antimicrobial coatings on implants and catheters and as antimicrobial fillers for wound dressings and dental fillings. Using this approach, the materials and devices can be protected against infection for weeks, months or even years as required. Pertinax can also be used to replace the conventional, aqueous CHX present in many existing products, to provide a longer antimicrobial and antifungal protection. For example, oral rinses, topical skin creams and veterinary shampoos contain aqueous CHX but their efficacy is limited to a few hours; replacing CHX with Pertinax would provide an antimicrobial environment for days or even weeks.